Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist
- PMID: 23181587
- DOI: 10.1021/jm301268u
Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist
Abstract
Dysfunction of glutamatergic neurotransmission has been implicated in the pathogenesis of epilepsy and numerous other neurological diseases. Here we describe the discovery of a series of 1,3,5-triaryl-1H-pyridin-2-one derivatives as noncompetitive antagonists of AMPA-type ionotropic glutamate receptors. The structure-activity relationships for this series of compounds were investigated by manipulating individual aromatic rings located at positions 1, 3, and 5 of the pyridone ring. This culminated in the discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel, 6), a novel, noncompetitive AMPA receptor antagonist that showed potent activity in an in vitro AMPA-induced Ca2+ influx assay (IC50=60 nM) and in an in vivo AMPA-induced seizure model (minimum effective dose of 2 mg/kg po). Perampanel is currently in regulatory submission for partial-onset seizures associated with epilepsy.
Similar articles
-
Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy.Epilepsia. 2011 Jul;52(7):1331-40. doi: 10.1111/j.1528-1167.2011.03109.x. Epub 2011 Jun 2. Epilepsia. 2011. PMID: 21635236
-
Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.J Pharmacol Exp Ther. 2014 Oct;351(1):124-33. doi: 10.1124/jpet.114.212779. Epub 2014 Jul 15. J Pharmacol Exp Ther. 2014. PMID: 25027316
-
Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.Expert Opin Pharmacother. 2013 Feb;14(2):225-35. doi: 10.1517/14656566.2013.754883. Epub 2012 Dec 23. Expert Opin Pharmacother. 2013. PMID: 23259931 Review.
-
Development of perampanel in epilepsy.Acta Neurol Scand Suppl. 2013;(197):3-8. doi: 10.1111/ane.12098. Acta Neurol Scand Suppl. 2013. PMID: 23480150 Review.
-
Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist.Acta Neurol Scand Suppl. 2013;(197):19-24. doi: 10.1111/ane.12100. Acta Neurol Scand Suppl. 2013. PMID: 23480152 Free PMC article. Review.
Cited by
-
Optical control of AMPA receptors using a photoswitchable quinoxaline-2,3-dione antagonist.Chem Sci. 2017 Jan 1;8(1):611-615. doi: 10.1039/c6sc01621a. Epub 2016 Aug 24. Chem Sci. 2017. PMID: 28451208 Free PMC article.
-
The Antiepileptic Drug Oxcarbazepine Inhibits the Growth of Patient-Derived Isocitrate Dehydrogenase Mutant Glioma Stem-like Cells.Cells. 2023 Apr 20;12(8):1200. doi: 10.3390/cells12081200. Cells. 2023. PMID: 37190109 Free PMC article.
-
Structural Bases of Noncompetitive Inhibition of AMPA-Subtype Ionotropic Glutamate Receptors by Antiepileptic Drugs.Neuron. 2016 Sep 21;91(6):1305-1315. doi: 10.1016/j.neuron.2016.08.012. Epub 2016 Sep 8. Neuron. 2016. PMID: 27618672 Free PMC article.
-
RNA aptamers for AMPA receptors.Neuropharmacology. 2021 Nov 1;199:108761. doi: 10.1016/j.neuropharm.2021.108761. Epub 2021 Sep 9. Neuropharmacology. 2021. PMID: 34509496 Free PMC article. Review.
-
Altered Calcium Permeability of AMPA Receptor Drives NMDA Receptor Inhibition in the Hippocampus of Murine Obesity Models.Mol Neurobiol. 2022 Aug;59(8):4902-4925. doi: 10.1007/s12035-022-02834-2. Epub 2022 Jun 3. Mol Neurobiol. 2022. PMID: 35657456
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous